Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.

The Promise of Universal Plasma

HemoDefend-BGA is a development-stage filter designed to create “universal plasma” – plasma that does not need blood-typing and can be given off-the-shelf to anyone in need regardless of blood type – by removing anti-A and anti-B antibodies that make plasma blood-type specific.
*HemoDefend-BGA is a pre-clinical product under development that is not yet approved.

Many applications of life-saving plasma include trauma resuscitation, treatment of critically ill patients, and component purification, e.g.:

Clotting factors
Albumin
Intravenous immunoglobulin

In the U.S. alone, more than 10,000 units of fresh frozen plasma are administered daily, or 3.6 million units per year.

Replace standard plasma

 

With more than $16 million in funding from the U.S. Department of Defense, CytoSorbents has successfully developed and demonstrated a prototype HemoDefend-BGA adsorber that removes anti-A and anti-B antibodies from human plasma, with the goal of advancing our technology to human clinical trials and producing a one-size-fits-all low-titer “universal plasma” product that could replace standard plasma.

For partnership inquiries please contact us

Get in touch
CytoSorbents

Voices around the world

world map
Critical Care
Dr. Sandra Pena Salazar
San Salvador, El Salvador

In coronary patients with low ejection fraction, endocarditis, we use it almost routinely. It has been a valuable support. We have seen shorter hospital stays.

Critical Care
Dr. Klaus Kogelmann
Leer, Germany

Those who were treated early and based on short change intervals benefited the most from the therapy.

Critical Care
Dr. Giorgio Berlot
Trieste, Italy

Treat the patient as soon as possible within 48 hours and as much as possible. The more and earlier you treat, the better the outcome of the patient.